Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PASG vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PASG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–1 Matrix Metrics)

PASG Overall Winner 6-Pillar Tally: PASG 3 – 1 LYRA (2 Tie) Matrix Metrics: PASG 6 – 1 LYRA

As of Nov 17, 2026, Passage Bio, Inc. (PASG) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PASG carries a Unified Composite Score of 21.6/100 (STRONG SELL) at $4.21 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PASG 21.6/100 STRONG SELL), PASG captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: PASG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PASG vs LYRA
PASG NASDAQ Head-to-Head Winner
Passage Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.21
+1.94% 1D
Market Cap $13.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.64β · 90% Vol
Unified Composite Score
21.6 / 100 STRONG SELL
Tech 3.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.2 · SMA20: $3.65 · SMA50: $4.09
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (PASG 3 – 1 LYRA)

Columns: Metric · PASG · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale PASG
Revenue Growth (YoY) +0.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $13.7M $2.3M
3. Profitability & Quality PASG
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -212.3% -404.5%
4. Balance Sheet & Cash Flow PASG
Cash Generation (TTM) -$31M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $28M Net Cash -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.0% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PASG (6) vs LYRA (1)
Institutional Metric PASG LYRA Criterion Row Edge
Market Capitalization
Scale
$13.7M $2.3M Larger Scale PASG
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -87.2% Higher Growth PASG
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin PASG
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-212.3% -404.5% Higher ROE PASG
52-Week Range Position
Momentum
6% ($3–$20) 1% ($0–$38) Stronger Trend PASG
Beta / 30D Volatility
Risk Regime
1.64β · 90% Vol 0.33β · 248% Vol Lower Realized Risk PASG
Unified Institutional Score
Composite Signal
21.6 / 100 (STRONG SELL) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($28M Net Cash) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PASG +50.01 pp
PASG: -12.49% · LYRA: -62.5%
3M Horizon PASG +59.16 pp
PASG: -28.46% · LYRA: -87.62%
6M Horizon PASG +73.47 pp
PASG: -13.67% · LYRA: -87.14%
1Y Horizon PASG +73.47 pp
PASG: -13.67% · LYRA: -87.14%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PASG vs LYRA. Trailing 12-month operating profitability (PASG 0.0% vs LYRA -25032.0%) and valuation multiples (PASG N/M vs LYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PASG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-212.3% · N/M
LYRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$600,000
Gross MarginN/A
Op. Margin-25032.0%
ROE / Fwd P/E-404.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PASG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PASG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PASG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PASG vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Passage Bio, Inc. (PASG) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PASG carries a Unified Composite Score of 21.6/100 (STRONG SELL) at $4.21 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PASG 21.6/100 STRONG SELL), PASG captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY). Technical & Structure Timing Caution: PASG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PASG leads the Growth & Scale pillar: PASG posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). On trailing 12-month operating scale, PASG generates N/A in USD-normalized revenue versus $600,000 for LYRA. In operating R&D and SG&A reinvestment, PASG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. PASG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PASG (-212.3% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PASG carries 0.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 90% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.